"Promotion of patient care circles are all part of the solution for keeping seniors out of the hospital and independent as possible."

Dr. Rienhoff and his team are developing bomedemstat for the treatment of myeloproliferative neoplasms (MPNs) which are rare blood cancers.

"Lightbeam is a platform that facilitates end-to-end population health management for our ACOs, payers, provider groups, health systems...

Eric Rock is a pioneer in remote patient monitoring, consumer electronics and biometric devices combined with virtual visits.

The company is first targeting a patient population with a severe alcoholic injury to the liver who are not eligible for transplant.

Dr. Elizabeth Marshall focuses on the application of Natural Language Processing in drug development and healthcare.

Spinal Muscular Atrophy is the leading genetic causes of death in young children.

Sparrow is exploring blocking the formation of intracellular steroids to reduce the side effects of steroid medicines and conditions.

Two of our treatment candidates are PRX012, which is our anti-Aβ antibody and our Aβ-tau vaccine. We also have an anti-tau8 antibody.

Blackrock Neurotech is focused on expanding the options, understanding, and marketing of brain computer interfaces and neuro devices..

The lead clinical product candidate ATYR1923 is a potential disease-modifying therapy for patients with severe inflammatory lung disease.

a focus on the application of Natural Language Processing in drug development and healthcare.

Dan Temple is a patient advocate for those with Spinal Muscular Atrophy (SMA).

4medica's mission is really to formulate a one patient, one record paradigm, to access a number of data sources for a patient.

Hopefully, patients can live for years knowing they have the disease but not having it debilitate their daily life.

Aside from the physics of actually connecting and pulling the data, there are all sorts of IT-related issues of how to store the data...

Emily Park is on a mission to educate healthcare professionals and patients about medical PTSD.

The diseases PepGen is focused on are are Duchenne muscular dystrophy, and myotonic dystrophy.

Mnemo has just raised $990 million in a Series A round, reportedly the largest round to date in France..

TFF Pharma is developing an internal portfolio of products and also working with external partners to apply thin film freezing technology.